Celltrion, Inc., a biopharmaceutical manufacturer, opened a Global R&D Center in South Korea to support breakthrough therapies. The company is expanding its presence in the U.S. market, and has recently obtained breakthroughs for its efforts to make its treatments accessible to American patients with the July 2023 launch of its Humira biosimilar, Yuflyma and FDA application for a novel subcutaneous formulation of infliximab.

The center is a state-of-the-art R&D hub for developing next-generation drugs in biopharmaceuticals and small molecules with the largest number of researchers in South Korea. It leverages creative design to boost cross-functional synergies across all five of Celltrion’s R&D institutes based there.

The center offers research capabilities and technologies spanning all areas of biopharmaceutics, including the identification of candidate substances for new drugs, stem cell development, and expression through genetic recombination, mass production of biopharmaceutical products, equivalency evaluation for product approval, and research of product characteristics and mechanism.